Get the Stockscreener App
6.66
0.41%
0.00
Organon Co stock is traded at $6.66, with a volume of 2.65M.
It is up +0.41% in the last 24 hours and down -35.39% over the past month.
Organon & Co is a science-based pharmaceutical company that develops and delivers health solutions through a portfolio of prescription therapies within women's health, biosimilars, and established brands. The Company's operations include the following product portfolio: Women's health, Biosimilars and Established medicines. Geographically, it derives a majority of its revenue from Europe and Canada followed by the United States and then Asia Pacific and Japan. The company generates the majority of its revenue from the Established Brands product portfolio.
See More
Previous Close:
$6.66
Open:
$6.67
24h Volume:
2.65M
Relative Volume:
0.56
Market Cap:
$1.73B
Revenue:
$6.28B
Net Income/Loss:
$700.00M
P/E Ratio:
2.4738
EPS:
2.6922
Net Cash Flow:
$537.00M
1W Performance:
-25.20%
1M Performance:
-35.39%
6M Performance:
-49.18%
1Y Performance:
-62.54%
1-Day Range:
$6.64
$6.84
1-Week Range:
$6.39
$9.28
52-Week Range:
$6.39
$19.05
Organon Co Stock (OGN) Company Profile
Name
Organon Co
Sector
Industry
Phone
551-430-6000
Address
30 HUDSON STREET, JERSEY CITY
Compare OGN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OGN
Organon Co
|
6.665 | 1.73B | 6.28B | 700.00M | 537.00M | 2.6922 |
|
LLY
Lilly Eli Co
|
820.96 | 735.18B | 53.26B | 13.80B | -50.20M | 15.08 |
|
JNJ
Johnson Johnson
|
185.61 | 450.37B | 92.15B | 25.12B | 20.46B | 10.36 |
|
ABBV
Abbvie Inc
|
226.07 | 401.96B | 58.33B | 3.73B | 18.24B | 2.1013 |
|
NVS
Novartis Ag Adr
|
122.41 | 238.94B | 53.40B | 13.68B | 16.89B | 6.8864 |
|
MRK
Merck Co Inc
|
86.92 | 217.38B | 63.43B | 16.42B | 14.72B | 6.4861 |
Organon Co Stock (OGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-27-25 | Downgrade | Piper Sandler | Overweight → Underweight |
| May-02-25 | Downgrade | Evercore ISI | Outperform → In-line |
| Sep-06-24 | Downgrade | JP Morgan | Neutral → Underweight |
| Nov-03-23 | Downgrade | Goldman | Buy → Neutral |
| Sep-21-23 | Initiated | Barclays | Overweight |
| Mar-16-23 | Initiated | Raymond James | Outperform |
| Oct-14-22 | Downgrade | BofA Securities | Neutral → Underperform |
| Sep-06-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| Aug-05-22 | Downgrade | BofA Securities | Buy → Neutral |
| Apr-27-22 | Initiated | Goldman | Buy |
| Apr-06-22 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-07-21 | Initiated | Piper Sandler | Neutral |
| Sep-01-21 | Initiated | BofA Securities | Buy |
| Jul-22-21 | Initiated | Citigroup | Buy |
| Jun-15-21 | Initiated | JP Morgan | Neutral |
| Jun-11-21 | Initiated | Morgan Stanley | Equal-Weight |
| Jun-10-21 | Initiated | Evercore ISI | Outperform |
View All
Organon Co Stock (OGN) Latest News
Why Organon (OGN) Stock Is Down Today - TradingView
Organon’s Stock Tumbles Amidst Leadership Shake-Up - StocksToTrade
Organon hit hard over ousted CEO scandal - The Pharma Letter
The Bottom Fishing ClubOrganon: Deep Value In Drugs/Medical Products (NYSE:OGN) - Seeking Alpha
Organon Investigation Initiated By Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates Claims On Behalf of Investors of Organon & Co.OGN - FinancialContent
Organon Investor Alert: CEO Resigns Amid Audit ProbeSecurities Fraud Investigation on Behalf of Organon InvestorsContact Kehoe Law Firm, P.C.OGN - ACCESS Newswire
Morgan Stanley Maintains Organon & Co(OGN.US) With Hold Rating, Maintains Target Price $10 - 富途牛牛
Organon’s Stock Sinks, But Deep Value Beckons For Patient Investors - Finimize
Organon makes personnel moves after internal probe finds ‘improper’ sales practices - ROI-NJ
Organon appoints interim CEO amid sales practice investigation By Investing.com - Investing.com Canada
Organon & Co stock hits 52-week low at 7.26 USD - Investing.com Canada
Organon & Co.’s Promising Phase 3 Study on Tapinarof Cream for Pediatric Plaque Psoriasis - TipRanks
Organon & Co. (OGN) Faces Investor Scrutiny Amid Improper - GlobeNewswire
Kaplan Fox is Investigating Organon & Co. (OGN) Following an Announcement of Findings of an Audit Committee Investigation and CEO Resignation - NewMediaWire
Organon CEO resigns after probe into 'improper' sales practices - FirstWord Pharma
Biotech Outshines As Healthcare Stocks See Mixed Moves - Finimize
This Drugmaker Made ‘Improper’ Sales to Meet Guidance. The Stock Plummets 22%. - Barron's
Organon CEO resigns amid Nexplanon sales probe (updated) - NJBIZ
Organon CEO stands down amid contraceptive sales malpractice probe - Yahoo Finance
Stocks making the biggest moves midday: Qualcomm, Fermi, Dyne Therapeutics, Organon, Snowflake and more - CNBC
This Drugmaker Made ‘Improper’ Sales to Meet Guidance. The Stock Plummets 25%. - Barron's
Piper Sandler Downgrades Organon to Underweight From Overweight, $5 Price Target - MarketScreener
Organon Appoints Interim CEO and Board Chair; Reports Results of Audit Committee Investigation - New Jersey Business Magazine
Organon cut to Underweight at Piper Sandler on internal control concerns - Seeking Alpha
Organon Appoints Company Executive Joseph Morrissey as Interim CEO - citybiz
Organon & Co stock hits 52-week low at 7.26 USD By Investing.com - Investing.com South Africa
Organon CEO Resigns After Probe Finds Improper Sales Practices - Bloomberg.com
Organon appoints company executive Joseph Morrissey as interim CEO and board chair Carrie Cox as executive chair; announces results of audit committee investigation - MarketScreener
Organon Appoints Company Executive Joseph Morrissey As Interim CEO And Board Chair Carrie Cox As Executive Chair Announces Results Of Audit Committee Investigation - TradingView
Organon CEO Kevin Ali to resign after probe into contraceptive sales - Reuters
Organon CEO Kevin Ali Resigns Amid Audit Probe Into Wholesaler Sales Practices - Stocktwits
Organon & Co. Announces CEO Changes - MarketScreener
Organon stock tumbles after CEO resigns amid sales practice investigation By Investing.com - Investing.com UK
Organon falls as CEO resigns after probe into contraceptive sales - TradingView
Organon CEO Kevin Ali to resign after probe into wholesaler sales practices - MarketScreener
Organon Appoints Company Executive Joseph Morrissey as Interim CEO and Board Chair Carrie Cox as Executive Chair; Announces Results of Audit Committee Investigation - Stock Titan
Co. (7XP) stock considered safe havenMarket Growth Review & Fast Exit and Entry Trade Guides - newser.com
Co. (7XP) stock in 20252025 Big Picture & Capital Efficiency Focused Ideas - newser.com
Co. (7XP) stock survive global slowdown2025 Sector Review & Safe Entry Point Alerts - newser.com
Assessing Organon Stock After a 39.5% Drop and Recent Portfolio Moves - Yahoo Finance
Organon (OGN) Laps the Stock Market: Here's Why - sharewise.com
Organon (OGN) Earnings Expected to Grow: Should You Buy? - Yahoo Finance
Organon & Co. (OGN) Is a Trending Stock: Facts to Know Before Betting on It - sharewise.com
Organon & Co. (OGN) Stock Analysis: Exploring a 40.69% Potential Upside Amidst Healthcare Sector Challenges - DirectorsTalk Interviews
Co. (7XP) stock good for long term investingJuly 2025 Recap & High Accuracy Buy Signal Tips - newser.com
(OGN) Movement Within Algorithmic Entry Frameworks - news.stocktradersdaily.com
Is Prolonged Revenue and EPS Decline Altering the Investment Case for Organon (OGN)? - Yahoo Finance
Is Organon Co a good long term investmentPrice Momentum Alerts & Superior Capital Investment - earlytimes.in
Organon (OGN) Stock Declines While Market Improves: Some Information for Investors - sharewise.com
J.P. Morgan Keeps Their Sell Rating on Organon (OGN) - The Globe and Mail
Organon: Muted H2 2025 Ahead, But Distressed Valuation And Manageable Debt Makes It A Compelling Buy - Seeking Alpha
Organon Co Stock (OGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.68%
0.33%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):